Moreover, the fact that PRIMA-1 was effective against all the HMCLs tested, irrespective of their p53 status (albeit at higher concentrations), really underscores its versatility in targeting myeloma cases with different genetic alterations. This evidence concerns the gene PRIMA1 and plasma cell myeloma.